Core Insights - The article highlights the rapid advancements in AI-driven drug development in Hangzhou, particularly in the Qiantang (New) District, which is becoming a hub for the integration of AI and biomedicine [4][6][8] Group 1: AI in Drug Development - Derui Zhiyao's first AI-designed oral small molecule drug, MDR-001, has successfully entered clinical trials, offering new treatment options for overweight patients [4] - The company has developed a one-stop drug research and development platform, Molecule Pro™, which significantly reduces the time and cost of drug development by 50% and saves 1.5 to 3 years compared to traditional methods [6][7] - The Zhejiang University Intelligent Innovation Drug Research Institute has been instrumental in supporting local pharmaceutical companies with AI technology, leading to the incubation of seven drug companies in the Qiantang area [7][8] Group 2: Industry Growth and Investment - Qiantang District has established a comprehensive ecosystem for biomedicine, including preclinical research, clinical trial platforms, and full-chain industrialization processes [9] - The district's industrial fund has exceeded 45 billion yuan, with investments in 266 companies, including 71 unicorns, showcasing strong financial backing for the biomedicine sector [9] - Recent discussions at the Zhejiang Provincial High-level Talent Conference highlighted the potential of AI in transforming biomedical understanding and practices, indicating a forward-looking approach to industry development [8][9]